目的 探讨胆舒胶囊联合复方阿嗪米特治疗慢性胆囊炎的临床疗效。方法 回顾性分析2016年2月—2017年2月在广州市第十二人民医院进行治疗的90例慢性胆囊炎患者的临床资料，所有患者应用随机数字表随机分为对照组（45例）和治疗组（45例）。对照组口服复方阿嗪米特肠溶片，2片/次，3次/d；治疗组在对照组的基础上口服胆舒胶囊，2粒/次，3次/d；两组均连续治疗4周。观察两组患者临床疗效，同时比较治疗前后两组患者临床症状积分、血清细胞因子水平变化。结果 治疗后，对照组和治疗组的总有效率分别为80.00%、95.56%，两组比较差异具有统计学意义（P< 0.05）。两组的临床症状评分均显著降低，同组治疗前后比较差异有统计学意义（P< 0.05）；且治疗组这些临床症状积分明显低于对照组，两组比较差异具有统计学意义（P< 0.05）。两组血清白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、β内啡肽（β-EP）水平均显著降低，同组治疗前后比较差异有统计学意义（P< 0.05）；且治疗组这些血清细胞因子水平明显低于对照组，两组比较差异具有统计学意义（P< 0.05）。结论 胆舒胶囊联合复方阿嗪米特肠溶片治疗慢性胆囊炎不仅能够显著改善临床症状，而且还可降低机体炎症反应，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Danshu Capsules combined with Compound Azimtamide Entieric-coated Tablets in treatment of chronic cholecystitis. Methods The clinical data of patients (90 cases) with chronic cholecystitis in Guangzhou 12th People's Hospital from February 2016 to February 2017 were retrospectively analyzed. Patients were divided into control (45 cases) and treatment (45 cases) groups by random number table. Patients in the control group were po administered with Compound Azimtamide Entieric-coated Tablets, two tablets/time, three times daily. Patients in the treatment group were po administered with Danshu Capsules on the basis of the control group, two grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and clinical symptom scores and serum cytokine levels in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.00% and 95.56%, respectively, and there was difference between two groups (P < 0.05). After treatment, the clinical symptom scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the clinical symptom scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, IL-6, TNF-α, and β-EP in two groups significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the serum cytokine levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Danshu Capsules combined with Compound Azimtamide Entieric-coated Tablets in treatment of chronic cholecystitis can not only significantly improve the clinical symptoms, but also reduce the body's inflammatory response, which has a certain clinical application value.